Dr. Roger Lo is Professor of Medicine/Dermatology, Associate Chief of Dermatology and Director of the Dermatology STAR Program at UCLA’s David Geffen School of Medicine.  He earned his BS in Biology with Honors and Distinction in 1994 from Stanford University and his MD and PhD degrees from the Tri-institutional (Weill Cornell, Memorial Sloan-Kettering, and Rockefeller) MD-PhD Program in 2002. After completing residency and postdoctoral work at UCLA, he joined the faculty in 2008. Work from his group has been recognized for providing the major scientific rationale toward the use of inhibitors of BRAF and MEK in combination to effectively treat melanoma – a therapeutic approach that is now globally considered the standard of care. Studies from his group have provided rationale to additional clinical trials and foundational knowledge on the roles of tumor heterogeneity, non-genomic processes and the tumor microenvironment in determining clinical responses to mutation-targeted and immunotherapies. His work has been published in Nature, New England Journal of Medicine, Cancer Discovery, Cancer Cell, and Cell. Dr. Lo was elected to the American Society for Clinical Investigation in 2012 and American Dermatological Association in 2015. In 2013 Dr. Lo received the 33^rd Annual Award for Outstanding Achievement in Cancer Research from the American Association for Cancer Research (AACR). In 2017, Dr. Lo received the inaugural AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research. Dr. Lo has received the Innovative Research Grant from Stand Up to Cancer and the Milstein Innovation Award for the American Skin Association. He currently serves on the Editorial Board of Cancer Discovery.